One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical trial to evaluate the effect of early and rapid treprostinil therapy to reduce mean pulmonary arterial pressure (mPAP) and reverse right ventricle (RV) remodeling in pulmonary arterial hypertension.
At the heart of the ARTISAN study is an innovative approach: using the implantable CardioMEMS device to continuously monitor haemodynamics and guide the titration of treprostinil, allowing treatment to be tailored to specific physiological goals rather than relying on symptoms alone. This strategy enabled patients to safely reach higher prostacyclin doses while achieving sustained reductions in pulmonary pressure over time.
The interim findings are very promising:
- Substantial reduction in mean pulmonary artery pressure (~25%) and a >40% reduction in total pulmonary resistance, reflecting true RV afterload relief
- • Reverse cardiac remodeling, including improved right ventricular structure and normalization of RVEDV/LVEDV
- • Improved left ventricular filling, highlighting the downstream benefits of unloading the right heart
- • Restoration of RV–PA coupling, a marker closely linked to outcomes
The study by Dr. Benza and his collaborators demonstrate that parenteral prostacyclins, used strategically and guided by real-time haemodynamic data, retain enormous therapeutic potential.
Read more at this link on Prof. Raymond Benza’s LinkedIn page